264 related articles for article (PubMed ID: 8891583)
21. Neuropeptides modulate human eosinophil chemotaxis.
Numao T; Agrawal DK
J Immunol; 1992 Nov; 149(10):3309-15. PubMed ID: 1385521
[TBL] [Abstract][Full Text] [Related]
22. The effect of salmeterol and nimesulide on chemotaxis and synthesis of PAF and LTC4 by human eosinophils.
Tool AT; Mul FP; Knol EF; Verhoeven AJ; Roos D
Eur Respir J Suppl; 1996 Aug; 22():141s-145s. PubMed ID: 8871060
[TBL] [Abstract][Full Text] [Related]
23. The effects of elevated cyclic AMP levels on histamine-H1-receptor-stimulated inositol phospholipid hydrolysis and calcium mobilization in the smooth-muscle cell line DDT1MF-2.
Dickenson JM; White TE; Hill SJ
Biochem J; 1993 Jun; 292 ( Pt 2)(Pt 2):409-17. PubMed ID: 8389134
[TBL] [Abstract][Full Text] [Related]
24. Involvement of cyclic nucleotide-dependent protein kinases in cyclic AMP-mediated vasorelaxation.
Eckly-Michel A; Martin V; Lugnier C
Br J Pharmacol; 1997 Sep; 122(1):158-64. PubMed ID: 9298542
[TBL] [Abstract][Full Text] [Related]
25. Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.
Kida T; Fujii A; Sakai O; Iemura M; Atsumi I; Wada T; Sakaki H
Exp Eye Res; 2010 Jul; 91(1):85-91. PubMed ID: 20412793
[TBL] [Abstract][Full Text] [Related]
26. Investigation of the inhibitory effects of PGE2 and selective EP agonists on chemotaxis of human neutrophils.
Armstrong RA
Br J Pharmacol; 1995 Dec; 116(7):2903-8. PubMed ID: 8680723
[TBL] [Abstract][Full Text] [Related]
27. Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium nitroprusside.
Turner NC; Lamb J; Worby A; Murray KJ
Br J Pharmacol; 1994 Apr; 111(4):1047-52. PubMed ID: 8032589
[TBL] [Abstract][Full Text] [Related]
28. Effects of platelet activating factor on the chemotaxis of normodense eosinophils from normal subjects.
Tamura N; Agrawal DK; Suliaman FA; Townley RG
Biochem Biophys Res Commun; 1987 Feb; 142(3):638-44. PubMed ID: 3030295
[TBL] [Abstract][Full Text] [Related]
29. Requirement of additional adenylate cyclase activation for the inhibition of human eosinophil degranulation by phosphodiesterase IV inhibitors.
Ezeamuzie CI
Eur J Pharmacol; 2001 Apr; 417(1-2):11-8. PubMed ID: 11301054
[TBL] [Abstract][Full Text] [Related]
30. Cyclic AMP-elevating agents prolong or inhibit eosinophil survival depending on prior exposure to GM-CSF.
Hallsworth MP; Giembycz MA; Barnes PJ; Lee TH
Br J Pharmacol; 1996 Jan; 117(1):79-86. PubMed ID: 8825346
[TBL] [Abstract][Full Text] [Related]
31. Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation.
Souness JE; Carter CM; Diocee BK; Hassall GA; Wood LJ; Turner NC
Biochem Pharmacol; 1991 Jul; 42(4):937-45. PubMed ID: 1651083
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of PAF-induced expression of CD11b and shedding of L-selectin on human neutrophils and eosinophils by the type IV selective PDE inhibitor, rolipram.
Berends C; Dijkhuizen B; de Monchy JG; Dubois AE; Gerritsen J; Kauffman HF
Eur Respir J; 1997 May; 10(5):1000-7. PubMed ID: 9163638
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by 'type IV'-selective PDE inhibitors.
Dent G; Giembycz MA; Rabe KF; Barnes PJ
Br J Pharmacol; 1991 Jun; 103(2):1339-46. PubMed ID: 1653070
[TBL] [Abstract][Full Text] [Related]
34. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response.
Griswold DE; Webb EF; Breton J; White JR; Marshall PJ; Torphy TJ
Inflammation; 1993 Jun; 17(3):333-44. PubMed ID: 7687237
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of antigen-induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP-specific phosphodiesterase inhibitor, rolipram.
Underwood DC; Osborn RR; Novak LB; Matthews JK; Newsholme SJ; Undem BJ; Hand JM; Torphy TJ
J Pharmacol Exp Ther; 1993 Jul; 266(1):306-13. PubMed ID: 8392555
[TBL] [Abstract][Full Text] [Related]
36. Evidence for mediation of acetyl glyceryl ether phosphorylcholine stimulation of adenosine 3',5'-(cyclic)monophosphate levels in human polymorphonuclear leukocytes by leukotriene B4.
Hopkins NK; Lin AH; Gorman RR
Biochim Biophys Acta; 1983 Oct; 763(3):276-83. PubMed ID: 6313071
[TBL] [Abstract][Full Text] [Related]
37. Effects of isozyme-selective phosphodiesterase inhibitors on eosinophil infiltration in the guinea-pig lung.
Lagente V; Moodley I; Perrin S; Mottin G; Junien JL
Eur J Pharmacol; 1994 Apr; 255(1-3):253-6. PubMed ID: 8026552
[TBL] [Abstract][Full Text] [Related]
38. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
[TBL] [Abstract][Full Text] [Related]
39. Inhibitory effects of formoterol on platelet-activating factor induced eosinophil chemotaxis and degranulation.
Eda R; Sugiyama H; Hopp RJ; Okada C; Bewtra AK; Townley RG
Int Arch Allergy Immunol; 1993; 102(4):391-8. PubMed ID: 8241801
[TBL] [Abstract][Full Text] [Related]
40. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
